• Exelixis recently reported final overall survival results from the phase 3 STELLAR-303 trial, showing a non-statistically significant trend favoring zanzalintinib plus atezolizumab over regorafenib in metastatic colorectal cancer patients without active liver metastases, with no new safety issues identified.
• Although the non-liver metastases subgroup missed statistical significance, these data sit alongside previously published overall survival benefit in the full trial population and an accepted FDA application, sharpening focus on how regulators and clinicians will view zanzalintinib’s total evidence package in colorectal cancer.
• We’ll now examine how this mixed but generally supportive STELLAR-303 evidence, especially the non-liver metastases subgroup trend, influences Exelixis’ investment narrative.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Exelixis Investment Narrative Recap

To own Exelixis today, you have to believe that management can gradually reduce its dependence on CABOMETYX by turning late stage assets like zanzalintinib into meaningful commercial franchises. The mixed STELLAR-303 subgroup result does not appear to alter the key near term catalyst, which is the FDA decision on the zanzalintinib colorectal cancer filing in December 2026, but it does underline the ongoing risk that parts of the pipeline may not fully translate into future revenue diversification.

The most relevant recent announcement here is the US FDA’s February 2026 acceptance of Exelixis’ New Drug Application for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer, with a target action date of December 3, 2026. That filing is anchored in the statistically significant overall survival benefit previously reported in the full STELLAR-303 population, so this new non liver metastases subgroup readout mainly refines, rather than redefines, the expectations around that upcoming regulatory decision.

However, investors should be aware that, despite strong recent earnings and buybacks, Exelixis still faces concentrated product risk and increasing pricing pressure that could...

Exelixis' narrative projects $3.3 billion revenue and $1.2 billion earnings by 2029.

Uncover how Exelixis' forecasts yield a $49.65 fair value, a 6% downside to its current price.

Exploring Other Perspectives

While consensus leans on zanzalintinib as a key future pillar, the most bearish analysts, who were assuming only about 1.4% annual revenue growth to roughly US$2.4 billion and lower margins, see the same STELLAR-303 update as fitting a tougher story where rising R&D costs and pricing pressure could weigh much more heavily on long term outcomes.

Explore 8 other fair value estimates on Exelixis - why the stock might be worth over 4x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Exelixis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exelixis' overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.